Drug Sponsors

TauRx receives $111.8M from Genting for Alzheimer's trials

Tuesday, November 20, 2012 02:02 PM

TauRx Pharmaceuticals of Singapore has received a further equity investment of $31.5 million from Genting Management (GMS), a Singapore-based subsidiary of Genting Berhad.

More... »

Wright Medical, BioMimetic to combine businesses

Monday, November 19, 2012 02:17 PM

Wright Medical Group, a global orthopedic medical device company, and BioMimetic Therapeutics, a biotech specializing in products to promote the healing of musculoskeletal injuries and diseases, have entered into a definitive agreement for a business combination of the Tennessee-based companies.

More... »

Aptuit and GSK extend strategic partnership

Monday, November 19, 2012 09:50 AM

Aptuit, a pharmaceutical services company, has reached an agreement on a multi-year extension of its strategic partnership with global healthcare company GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The Verona site—formerly known as GSK’s Medicines Research Centre—was acquired by Aptuit from GSK in 2010.

More... »

Allergan to acquire SkinMedica for $350M

Monday, November 19, 2012 09:22 AM

Allergan, a multi-specialty health care company, has entered into a definitive agreement to acquire SkinMedica, a privately held,  topical aesthetics skin care business.

More... »

Foundation Medicine, Ariad collaborate on genomic characterization in AP26113 oncology program

Wednesday, November 14, 2012 12:28 PM

Foundation Medicine, a molecular information company, and Ariad Pharmaceuticals, an emerging global oncology company, announced a genomic profiling collaboration to study AP26113, Ariad's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers.

More... »

Epic Sciences completes $13M Series B financing to advance cancer diagnostics

Wednesday, November 14, 2012 12:01 PM

Epic Sciences, a La Jolla, Calif.-based private biotech company that develops breakthrough cancer diagnostics, completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture Fund and Pfizer Venture Investments, in addition to undisclosed individual investors.

More... »

Gilead to build new R&D facility

Wednesday, November 14, 2012 11:13 AM

Gilead Alberta ULC, a wholly-owned subsidiary of biopharmaceutical company Gilead Sciences, has entered an agreement with Eco Industrial Business Park to purchase and develop 10 acres of land at 1250 Hayter Road, in North East Edmonton, Canada. The transaction is anticipated to close in January 2013.

More... »

Pearl Therapeutics raises $65M Series D to start PT003 phase III trial

Wednesday, November 14, 2012 10:48 AM

Pearl Therapeutics, a Redwood City, Calif.-based privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, has raised a $65 million Series D financing from current investors.

More... »

EastBridge Investment Group to merge with Cellular Biomedicine Group

Wednesday, November 14, 2012 09:55 AM

EastBridge Investment Group has entered into an agreement to merge with Cellular Biomedicine Group (CBMG), a translational medicine company with serial preclinical and clinical research projects, as well as multiple planned clinical trials in the Greater China market. The combined company will be headquartered in Palo Alto, Calif.

More... »

Boehringer Ingelheim launches Hep C online resource

Tuesday, November 13, 2012 01:39 PM

Boehringer Ingelheim has launched HepCRedefined.com, an online portal to help improve the lives of those living with the hepatitis C virus (HCV) through education, information and understanding. The portal aims to redefine the HCV journey by providing downloadable and shareable resources to healthcare providers, advocates, caregivers and patients.

More... »